脑部放疗，上午比下午敏感许多！
0 M2 a4 E, D# p: v" H0 I2 L: G: ?5 H, s8 B5 N2 n: Y
2 ^' |: E9 p. M" RCancer 2011 Jan 15;117(2):414-20. doi: 10.1002/cncr.25423. Epub 2010 Sep 9.
! m8 b2 z4 `0 c9 L/ l! d% pGamma knife radiosurgery for brain metastasis of nonsmall cell lung cancer: is there a difference in outcome between morning and afternoon treatment? |4 c$ ~8 d3 i5 }8 ~. d
Rahn DA 3rd, Ray DK, Schlesinger DJ, Steiner L, Sheehan JP, O'Quigley JM, Rich T.
) c( Y6 ]6 x' D7 z8 y2 lSourceDepartment of Radiation Oncology, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908, USA. q1 }' j A+ R2 g, ]& Y+ }
# P; x* R( A9 T- t! I% q
Abstract
( Q& g: l- P/ F, l K+ DBACKGROUND: Circadian cell-cycle progression causes fluctuating radiosensitivity in many tissues, which could affect clinical outcomes. The purpose of this study was to determine whether outcomes of single-session gamma knife radiosurgery (GKRS) for metastatic nonsmall cell lung cancer (NSCLC) differ based on treatment time.3 p" Z* S: T' o! D! T
% e2 i; G% t. s. \2 v
METHODS: Fifty-eight patients received GKRS between 10:00 am and 12:30 pm and 39 patients received GKRS between 12:30 pm and 3:00 pm. The mean peripheral dose was 18.6 Gy. The mean tumor size was 7.3 cm³. Magnetic resonance imaging was used to score local control at 3 months. Cause of death (COD) was categorized as central nervous system (CNS)-related or systemic.8 T6 d o% B5 k9 f7 M0 E N$ t7 h$ y2 C
* T* k; u3 O5 U. e6 W6 ~4 o
RESULTS: Demographic and disease characteristics of the 2 groups were similar. Local control at 3 months was achieved in 97% (35/36) of patients who underwent GKRS early in the day versus 67% (8/12) of patients who underwent GKRS later in the day (chi-square, P = .014). Early GKRS was associated with better survival (median 9.5 months) than late GKRS (median 5 months) (Kaplan-Meier log-rank test, P = .025). Factors contributing to better survival in a Cox regression model included early treatment time (P = .004) and recursive partition analysis class (P < .001). Cause of death in the early treatment group was CNS-related in 6% (3/47) of patients versus 24% (8/34) of patients in the late treatment group (chi-square test, P = .026).7 Z2 c: O2 F) o; ]9 b& l3 t+ Y" p. }, q
0 o7 I% `4 B. R2 C5 q k8 `. p( cCONCLUSIONS: GKRS for metastatic NSCLC had better local control, better survival, and a lower rate of CNS-related cause of death when given earlier in the day versus later in the day. These retrospective data should encourage future study in brain radiosurgery and non-CNS stereotactic body radiotherapy series.
/ G3 k* n. _- Z8 O6 l
; C- a s k8 d- s8 O: K |
奥西替尼耐药后续治疗，出现腹水
治疗经过：
2010确诊腺癌
治疗方案：右肺上叶切除，10年民诺宾2次，顺铂+盖诺2次。
三代伏美换一代特罗凯获益率问题
家父25年2月因肩膀疼痛确诊肺腺癌晚期4B，双肺转，多发骨转，脑转（非典型），
盲试靶向药 29个月，治疗分享
时间：2025/1/27 盲试靶向药第29个月。
本月治疗方案：7080（14mg）。2024年11月底
完成手术，病理也出来了，烦请各位老
之前因为心脏问题，去心内造影，前降支75%狭窄，回到心胸外科手术，目前主治医生说是
生存期超4年！首个击败奥希替尼的药
作者：seacat
2025年3月26日，巴黎举行的2025欧洲肺癌大会（ELCC 2025）报道了III期研
显身卡
